Revolutionizing Gut Health: Bactolife Secures $32.8M in Series A Funding to Expand Reach of Innovative Binding Proteins

We are thrilled to announce that Bactolife has successfully raised an impressive $32,799,999 in our latest funding round, a significant milestone that underscores our commitment to enhancing global gut health and combating antimicrobial resistance. As a pioneering Danish biotech firm, we specialize in innovative food ingredients known as Binding Proteins, which have the unique ability to selectively bind and block harmful microbial activity while preserving the beneficial microbiome. This revolutionary approach supports a diverse population, catering to the nutritional needs of mothers, children, the elderly, immune-compromised individuals, travelers, and even animals. Our mission is not just to develop these cutting-edge ingredients but to ensure their accessibility—our competitive pricing strategy reflects this dedication. The support from esteemed investors including Novo Holdings, the Bill & Melinda Gates Foundation, and Innovation Fund Denmark has been instrumental in advancing our efforts. With this new capital, we will accelerate our research and development initiatives, expand our production capabilities, and work towards making Binding Proteins a common part of diets worldwide. By integrating these natural and versatile ingredients into food, beverages, and supplements, we aim to revolutionize gut health and promote resilient microbiomes across the globe. Join us on this transformative journey as we aspire to change the future of gut health, one Binding Protein at a time. Thank you for supporting our vision—together, we can make a lasting impact on health and nutrition worldwide.